191 related articles for article (PubMed ID: 30460991)
21. Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
Casadó-Llombart S; Ajami T; Consuegra-Fernández M; Carreras E; Aranda F; Armiger N; Alcaraz A; Mengual L; Lozano F
Prostate; 2022 Oct; 82(14):1331-1337. PubMed ID: 35767366
[TBL] [Abstract][Full Text] [Related]
22. T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1.
da Glória VG; Martins de Araújo M; Mafalda Santos A; Leal R; de Almeida SF; Carmo AM; Moreira A
J Immunol; 2014 Jul; 193(1):391-9. PubMed ID: 24890719
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine phosphorylation of CD6 by stimulation of CD3: augmentation by the CD4 and CD2 coreceptors.
Wee S; Schieven GL; Kirihara JM; Tsu TT; Ledbetter JA; Aruffo A
J Exp Med; 1993 Jan; 177(1):219-23. PubMed ID: 7678115
[TBL] [Abstract][Full Text] [Related]
24. Identification of a mouse protein homologous to the human CD6 T cell surface protein and sequence of the corresponding cDNA.
Robinson WH; Prohaska SS; Santoro JC; Robinson HL; Parnes JR
J Immunol; 1995 Nov; 155(10):4739-48. PubMed ID: 7594475
[TBL] [Abstract][Full Text] [Related]
25. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation.
Osorio LM; Garcia CA; Jondal M; Chow SC
Cell Immunol; 1994 Mar; 154(1):123-33. PubMed ID: 7509726
[TBL] [Abstract][Full Text] [Related]
26. Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation.
Osorio LM; Ordonez C; Garcia CA; Jondal M; Chow SC
Cell Immunol; 1995 Nov; 166(1):44-52. PubMed ID: 7585980
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains.
Kobarg J; Whitney GS; Palmer D; Aruffo A; Bowen MA
Eur J Immunol; 1997 Nov; 27(11):2971-80. PubMed ID: 9394826
[TBL] [Abstract][Full Text] [Related]
28. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains.
Gimferrer I; Ibáñez A; Farnós M; Sarrias MR; Fenutría R; Roselló S; Zimmermann P; David G; Vives J; Serra-Pagès C; Lozano F
J Immunol; 2005 Aug; 175(3):1406-14. PubMed ID: 16034076
[TBL] [Abstract][Full Text] [Related]
29. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry.
Bowen MA; Bajorath J; Siadak AW; Modrell B; Malacko AR; Marquardt H; Nadler SG; Aruffo A
J Biol Chem; 1996 Jul; 271(29):17390-6. PubMed ID: 8663238
[TBL] [Abstract][Full Text] [Related]
30. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells.
Zimmerman AW; Joosten B; Torensma R; Parnes JR; van Leeuwen FN; Figdor CG
Blood; 2006 Apr; 107(8):3212-20. PubMed ID: 16352806
[TBL] [Abstract][Full Text] [Related]
31. Activation of T lymphocytes via monoclonal antibodies against rat cell surface antigens with particular reference to CD2 antigen.
Beyers AD; Barclay AN; Law DA; He Q; Williams AF
Immunol Rev; 1989 Oct; 111():59-77. PubMed ID: 2576418
[TBL] [Abstract][Full Text] [Related]
32. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.
Nair P; Melarkode R; Rajkumar D; Montero E
Clin Exp Immunol; 2010 Oct; 162(1):116-30. PubMed ID: 20726988
[TBL] [Abstract][Full Text] [Related]
33. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.
Bikah G; Lynd FM; Aruffo AA; Ledbetter JA; Bondada S
Int Immunol; 1998 Aug; 10(8):1185-96. PubMed ID: 9723705
[TBL] [Abstract][Full Text] [Related]
34. Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction.
Starling GC; Whitney GS; Siadak AW; Llewellyn MB; Bowen MA; Farr AG; Aruffo AA
Eur J Immunol; 1996 Apr; 26(4):738-46. PubMed ID: 8625962
[TBL] [Abstract][Full Text] [Related]
35. CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses.
Brown MH
Curr Drug Targets; 2016; 17(6):619-29. PubMed ID: 26302795
[TBL] [Abstract][Full Text] [Related]
36. CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn.
Burgess KE; Yamamoto M; Prasad KV; Rudd CE
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9311-5. PubMed ID: 1384049
[TBL] [Abstract][Full Text] [Related]
37. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes.
Singer NG; Mitra R; Lialios F; Richardson BC; Marks RM; Pesando JM; Fox DA; Nickoloff BJ
Immunol Lett; 1997 Jun; 58(1):9-14. PubMed ID: 9436462
[TBL] [Abstract][Full Text] [Related]
38. Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression.
Breuning J; Philip B; Brown MH
Immunology; 2019 Feb; 156(2):130-135. PubMed ID: 30300924
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies to CD6 preferentially stimulate T-cell clones with gamma/delta rather than alpha/beta antigen receptors.
Pawelec G; Bühring HJ
Hum Immunol; 1991 Jul; 31(3):165-9. PubMed ID: 1832421
[TBL] [Abstract][Full Text] [Related]
40. Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand.
Calvo J; Places L; Padilla O; Vilà JM; Vives J; Bowen MA; Lozano F
Eur J Immunol; 1999 Jul; 29(7):2119-29. PubMed ID: 10427974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
